Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review
| Autor: | Saad Ghazal-Aswad, Fathi Azribi, John Glaholm, Khalid Balaraj, Syed A. Hussain, Raya Almazrouei, Hidayath Ansari, Abdul Rahman Al Sumaida, Emad Dawoud, M.J. Hochmair, Pawan Kumar, Khaled Al-Qawasmeh, Heba Elhasin, Syed M.J. Akhter, Syed Rizwan, Yussra Eltigani Mohmmed, Jawaher Ansari, Omar Hassoun Hadid |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Pembrolizumab Malignancy Immune related adverse events Internal medicine medicine Case Reports and Case Series Wall-eyed internuclear ophthalmoplegia Stage (cooking) RC254-282 Vaginal cancer Chemotherapy Vaginal squamous cell carcinoma Radiotherapy business.industry Obstetrics and Gynecology Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immunotherapy Gynecology and obstetrics medicine.disease eye diseases Clinical trial Radiation therapy RG1-991 business Checkpoint inhibitors |
| Zdroj: | Gynecologic Oncology Reports, Vol 38, Iss, Pp 100878-(2021) Gynecologic Oncology Reports |
| ISSN: | 2352-5789 |
| Popis: | Highlights • Metastatic vaginal cancer, rare cancer with limited treatment options. • Pembrolizumab and radiotherapy led to complete response in a patient with metastatic vaginal cancer. • Wall-eyed bilateral internuclear ophthalmoplegia, a new immune related adverse event. Primary vaginal cancer is a rare malignancy with a lack of international guidelines and supporting clinical trial evidence to guide decision making. Historical results have shown poor outcomes with chemotherapy for stage IVB vaginal squamous cell carcinoma (SCC). The evolving role of checkpoint inhibitors in rare gynaecological cancers prompted us to investigate the role of pembrolizumab in this setting. The efficacy of pembrolizumab in vaginal SCC has never been investigated in any clinical trial. There is established data to support the use of concurrent chemoradiotherapy in gynaecological cancers, however, the data for concurrent use of immunotherapy and radiotherapy is still lacking but is the subject of several clinical trials. We herein present the first reported case of chemotherapy refractory vaginal SCC with complete response to pembrolizumab and concurrent pelvic radiotherapy. We also present wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) as a rare but new immune related adverse event. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|